
## Galatea kallergi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2310719/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 2011, 13, R59.	5.0	327
2	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Letters, 2010, 288, 99-106.	7.2	269
3	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. Clinical Cancer Research, 2008, 14, 2593-2600.	7.0	220
4	Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Annals of Oncology, 2012, 23, 1744-1750.	1.2	133
5	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Research, 2008, 10, R80.	5.0	128
6	Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Research, 2009, 11, R84.	5.0	111
7	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer, 2014, 14, 651.	2.6	97
8	Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients. Molecular Cancer Therapeutics, 2013, 12, 1886-1895.	4.1	96
9	Activation of FAK/PI3K/Rac1 Signaling Controls Actin Reorganization and Inhibits Cell Motility in Human Cancer Cells. Cellular Physiology and Biochemistry, 2007, 20, 977-986.	1.6	93
10	Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. Molecular Medicine, 2007, 13, 79-88.	4.4	80
11	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Research, 2011, 13, R60.	5.0	74
12	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775012.	3.2	61
13	Membrane androgen receptor activation in prostate and breast tumor cells: Molecular signaling and clinical impact. IUBMB Life, 2009, 61, 56-61.	3.4	57
14	Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells. Molecular Cancer Research, 2013, 11, 1248-1257.	3.4	54
15	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Research, 2014, 16, 485.	5.0	51
16	Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). Cellular Physiology and Biochemistry, 2016, 40, 411-419.	1.6	50
17	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS ONE, 2015, 10, e0123683.	2.5	49
18	Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biology and Therapy, 2009, 8, 1470-1477.	3.4	46

#	Article	IF	CITATIONS
19	Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Research and Treatment, 2009, 117, 525-534.	2.5	44
20	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Cellular Physiology and Biochemistry, 2017, 44, 594-606.	1.6	38
21	Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemotherapy and Pharmacology, 2014, 73, 685-693.	2.3	32
22	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Scientific Reports, 2021, 11, 2313.	3.3	32
23	Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. PLoS ONE, 2017, 12, e0181211.	2.5	30
24	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Oncotarget, 2017, 8, 5309-5322.	1.8	30
25	Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells. Experimental Cell Research, 2003, 288, 94-109.	2.6	25
26	Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. Breast Cancer Research, 2018, 20, 67.	5.0	25
27	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Research, 2015, 17, 113.	5.0	24
28	The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 587-597.	4.1	23
29	The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. Breast Cancer Research, 2019, 21, 86.	5.0	21
30	Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients. Cancers, 2021, 13, 2158.	3.7	18
31	Expression of insulinâ€like growth factorâ€1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. Molecular Oncology, 2018, 12, 21-32.	4.6	13
32	CD8 <sup>+</sup> PD-1 <sup>+</sup> T-cells and PD-L1 <sup>+</sup> circulating tumor cells in chemotherapy-naÃ`ve non-small cell lung cancer: towards their clinical relevance?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	3.2	13
33	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. Clinical Chemistry, 2021, 67, 1395-1405.	3.2	12
34	Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells. Cellular Physiology and Biochemistry, 2017, 42, 1366-1376.	1.6	10
35	CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989575.	3.2	10
36	Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis. International Journal of Developmental Biology, 2022, 66, 277-283.	0.6	9

GALATEA KALLERGI

#	Article	IF	CITATIONS
37	The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility. Cancer Biology and Therapy, 2020, 21, 533-540.	3.4	8
38	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. Cancers, 2022, 14, 1574.	3.7	8
39	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. Expert Review of Molecular Diagnostics, 2021, 21, 1037-1048.	3.1	7
40	Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Personalized Medicine, 2022, 12, 154.	2.5	7
41	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients' CTCs. Cancers, 2022, 14, 1731.	3.7	7
42	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(â^') breast cancer receiving salvage treatment with everolimus/exemestane. Cancer Chemotherapy and Pharmacology, 2021, 87, 277-287.	2.3	5
43	Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy Journal of Clinical Oncology, 2013, 31, e22101-e22101.	1.6	0
44	A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer Journal of Clinical Oncology, 2013, 31, e22105-e22105.	1.6	0
45	Abstract 1119: Non-adherent breast and non-small-cell lung cancer cell cultures as a promising CTCs' model for evaluation of the anti-tumor effects of artesunate. Cancer Research, 2022, 82, 1119-1119.	0.9	0